Autres langues Outlook Therapeutics, Inc.

Actions

OTLK

US69012T3059

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 27/08/2026			Varia. 5j.	Varia. 1 janv.
0,6411 ^USD	+2,86%		-5,20%	-59,42%

27/08	Outlook Therapeutics nomme Kevin Lundquist au poste de directeur financier	MT
17/08	Le traitement d'EyePoint contre la DMLA échoue en phase finale, l'action s'effondre	RE

Autres langues

27/08	Outlook Therapeutics Appoints Kevin Lundquist as CFO
27/08	Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
27/08	Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
17/08	EyePoint's drug for age-related eye disease fails late-stage trial, shares tank
17/08	Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing
14/08	Outlook Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026
14/08	Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
13/08	Top Premarket Decliners
13/08	Outlook Therapeutics Prices $55 Million Securities Offering; Shares Down Pre-Bell
13/08	Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
12/08	Outlook Therapeutics Starts Public Offering of Stock, Warrants
12/08	Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
06/08	Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
05/08	Outlook Therapeutics Secures FDA Approval For LYTENAVA™
24/07	Outlook Therapeutics Gains Following FDA Approval of Macular-Degeneration Drug -- Update
24/07	Outlook Therapeutics Announces LYTENAVA FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet Amd
24/07	Outlook Therapeutics Says Lytenava Gets FDA Approval for Retinal Disease Treatment
24/07	US FDA approves Outlook Therapeutics' eye disease drug
24/07	Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
17/07	Outlook Therapeutics Registers 17.3 Million Shares for Resale
29/06	Outlook Therapeutics Regains Nasdaq Compliance
17/06	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA as a Treatment for Wet AMD
16/06	Outlook Therapeutics Shares Surge After FDA Accepts Resubmitted Wet AMD Application
16/06	Outlook Therapeutics, Inc. Announces FDA Acceptance Of Resubmitted Biologics License Application For ONS-5010/LYTENAVA (Bevacizumab-Vikg) As A Treatment For Wet AMD
16/06	Outlook Therapeutics Announces FDA Acceptance of Resubmitted BLA for ONS-5010